To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Jane Biehl, Ph.D.

In the movie, Charlie Brown was asked what his New Year’s resolution was. With typical candor, he answered that instead of dreading the whole year he was dreading only one day at a time.
Mark Heaney, M.D., Ph.D.
Mark Heaney, M.D., Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the pros and cons of patients with myeloproliferative neoplasms (MPNs) researching their diagnosis online.
Catriona Jamieson, M.D., Ph.D.
Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, discusses what people diagnosed with myeloproliferative neoplasms (MPN) need to consider when choosing among providers and treatment options.
Gabriela Hobbs, M.D.
Gabriela Hobbs, M.D., discusses how to manage symptoms associated with a myeloproliferative neoplasm diagnosis.
Lindsey M. Lyle, M.S.
Lindsey M. Lyle, M.S., offers advice to patients with newly diagnosed myeloproliferative neoplasms.
Barbara Abernathy, Ph.D.

Barbara Abernathy, Ph.D., CEO of the Pediatric Oncology Support Team, explains how she is inspired by her work with children who have cancer.
Angeles Alvarez Secord, MD, speaks with her patient, Michelle Berke, about the side effect profiles for each of the poly (ADP-ribose) polymerase (PARP) inhibitors.
Silas Inman
The FDA has approved Bosulif (bosutinib) as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), based on findings from the phase 3 BFORE trial.
Kristie L. Kahl
Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other